UDG purchased two NY-based companies, SmartAnalyst, a strategic commercialization consulting and analytics business, and the communications agency Create NYC.
“Both transactions meet all of UDG’s acquisition criteria – good strategic and cultural fit, hit target financial hurdle rates and expand the group’s current capabilities,” said Brendan McAtamney, UDG’s CEO.
Ashfield, UDG’s commercialization services division, provides advisory, communication, commercial, and clinical services.
The acquisition of SmartAnalyst also will provide Ashfield with access to commercial development decision makers, as well as infrastructure in India, McAtamney told Outsourcing-Pharma.com.
“Ashfield will provide leverage and opportunities to grow Smart Analyst’s customer base outside the US through Ashfield’s global business,” he added.
In addition to strategic consulting services, SmartAnalyst provides Health Economics and Outcomes Research (HEOR) services – an area in which there is growing demand.
McAtamney said, “HEOR is a high growth area, driven by market dynamics such as the increasing complexity of drugs, the changing landscape of market access, cost and regulatory pressures, and the increased scrutiny of real-world outcomes.”
SmartAnalyst is being acquired for a total consideration of up to $24m and will be integrated into the UDG’s Advisory pillar.
Create NYC is healthcare creative communications agency, offering sales and marketing services for international pharmaceutical clients.
“The acquisition of Create NYC is in line with Ashfield’s strategy to expand into the area of creative communications, complementing its existing capabilities in core scientific communication,” said McAtamney.
Create NYC – which will become part of Ashfield Communications – is being acquired for a total consideration of up to $58.4m.